SB623 (Acego)
Chronic Traumatic Brain Injury (TBI)
Approved (Japan)Active
Key Facts
About SanBio Co Ltd
SanBio is a pioneering cell therapy company developing regenerative treatments for severe CNS injuries and disorders with high unmet medical need. Its core technology platform utilizes modified allogeneic bone marrow-derived mesenchymal stem cells (SB623) designed to be surgically implanted into the brain to stimulate natural repair processes. The company's lead program has achieved significant clinical milestones, including a conditional approval in Japan for TBI, positioning it as a leader in the neuro-regenerative medicine space. SanBio emphasizes scalable manufacturing and a global development strategy to bring accessible cell therapies to a broad patient population.
View full company profile